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Abstract
Cancer cells balance with the equilibrium of cell death and growth to expand and metastasize. The activity of mammalian
sterile20-like kinases (MST1/2) has been linked to apoptosis and tumor suppression via YAP/Hippo pathway-independent
and -dependent mechanisms. Using a kinase substrate screen, we identiﬁed here MST1 and MST2 among the top substrates
for ﬁbroblast growth factor receptor 4 (FGFR4). In COS-1 cells, MST1 was phosphorylated at Y433 residue in an FGFR4
kinase activity-dependent manner, as assessed by mass spectrometry. Blockade of this phosphorylation by Y433F mutation
induced MST1 activation, as indicated by increased threonine phosphorylation of MST1/2, and the downstream substrate
MOB1, in FGFR4-overexpressing T47D and MDA-MB-231 breast cancer cells. Importantly, the speciﬁc knockdown or
short-term inhibition of FGFR4 in endogenous models of human HER2+ breast cancer cells likewise led to increased MST1/
2 activation, in conjunction with enhanced MST1 nuclear localization and generation of N-terminal cleaved and
autophosphorylated MST1. Unexpectedly, MST2 was also essential for this MST1/N activation and coincident apoptosis
induction, although these two kinases, as well as YAP, were differentially regulated in the breast cancer models analyzed.
Moreover, pharmacological FGFR4 inhibition speciﬁcally sensitized the HER2+MDA-MB-453 breast cancer cells, not only
to HER2/EGFR and AKT/mTOR inhibitors, but also to clinically relevant apoptosis modulators. In TCGA cohort, FGFR4
overexpression correlated with abysmal HER2+ breast carcinoma patient outcome. Therefore, our results uncover a
clinically relevant, targetable mechanism of FGFR4 oncogenic activity via suppression of the stress-associated MST1/2-
induced apoptosis machinery in tumor cells with prominent HER/ERBB and FGFR4 signaling-driven proliferation.
Introduction
Cancer cells rely on oncogenic signaling by receptor tyr-
osine kinases (RTKs) to drive tumor initiation and pro-
gression [1]. Upon tumor evolution, RTKs contribute to the
development of resistance toward initially effective antic-
ancer treatments. Owing to inhibitable enzyme activity and
cell surface localization, RTKs thus serve as attractive
therapy targets. Among RTKs, ﬁbroblast growth factor
receptors (FGFRs) trigger intracellular signaling cascades
that control key cellular processes including survival, pro-
liferation, differentiation, and migration/invasion, as well as
angiogenesis—each dysregulated in cancer [2]. Four
homologous FGFRs are expressed in humans [2]. Out of
these, FGFR4 is dispensable for mouse development [3].
This coupled with speciﬁc FGFR4 induction in certain
cancers, along with structural differences and drug selec-
tivity relative to other FGFRs, supports the efﬁcacy of
FGFR4 as a therapeutic intervention [4–9].
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Despite advances in diagnosis and treatment, subsets of
breast cancer remain challenging to cure accounting for an
estimated 15% of cancer deaths in women [10]. As in other
cancers, the poor prognosis is partially attributed to therapy
resistance and anti-apoptosis responses of the cancer cells
[11]. FGFR4 overexpression and gene alterations, including
G388R single-nucleotide polymorphism, have been asso-
ciated with cancer invasion, drug resistance, and poor
prognosis [12–14]. In breast cancers, FGFR4 is over-
expressed in especially ERBB2/HER2-enriched tumors [4],
where it has been linked to tumor growth and apoptosis
resistance [4, 5, 15]. Acquired alterations have been
reported in FGFR4 and ERBB2/HER2 upon metastatic
cancer progression [16]. Despite these results, the molecular
mechanisms explaining how FGFR4 confers aggressive
cancer cell behavior remain incompletely understood.
Here, we screened for FGFR4 substrates using in vitro
kinase substrate microarrays. Unexpectedly, Hippo tumor
suppressor pathway components, including the serine/
threonine kinases MST1/2 (mammalian sterile20-like kina-
ses), were among the top tyrosine-phosphorylated sub-
strates. Cytoplasmic MST1/2 comprises the core
mammalian Hippo pathway kinase complex, which activa-
tion ultimately leads to serine phosphorylation-dependent
cytoplasmic retention and inactivation of the oncogenic
transcriptional regulators, YES-associated protein (YAP1),
and transcriptional co-activator with PDZ-binding motif
(TAZ) [17, 18]. Upon cell stress and apoptosis, caspase-3
cleavage removes the inhibitory C-terminal domains of
autophosphorylated MST1/2 to induce transport of acti-
vated N-terminal MST1/2 into the nucleus [19]. Although
overexpression results have shown that nuclear MST1/2 can
promote apoptosis [20–23], and reduced MST1/2 activity
associates with poor cancer prognosis [24–27], the func-
tional contributions of endogenous MST1/2 in physiologi-
cal or pathological apoptosis remain elusive [19]. Our
screening results led us to investigate in more detail the
functional interaction of FGFR4 and MST1/2. Altogether,
our results establish a unique oncogenic signaling
mechanism—the dominant FGFR4-mediated attenuation of
MST1/2-mediated, stress-associated apoptosis in HER2+
breast cancer cells.
Materials and methods
Kinase substrate identiﬁcation array
For in vitro FGFR4 substrate identiﬁcation, the protein
microarray containing 9483 human recombinant proteins
(Protoarray human protein microarrays version 5.0; Invi-
trogen, Carlsbad, CA, USA) was blocked and incubated
with the recombinant kinase domain of FGFR4 (50 nM;
Invitrogen) in the presence of [γ-33P] ATP. The array was
washed to remove unbound γ-33P, and exposed to X-ray
ﬁlm. The acquired array image was analyzed using Proto-
Array Prospector software (Invitrogen). The raw data were
subjected to background subtraction, signal scatter com-
pensation, and outlier detection. The Z-factor cutoff value
was set at ≥ 0.4. Phosphorylated proteins with a Z-score >
0.25 were considered as potential substrates.
Cell culture
Human ZR-75.1, MCF7, BT474, T47D, MDA-MB-453,
Hs578T, BT549, MDA-MB-231 (American Type Culture
Collection; ATCC, Manassas, VA, USA) and SUM159 [28]
breast carcinoma cells, and COS-1 cells (ATCC) were
cultured according to manufacturer’s instructions. The
MycoAlertPlus kit (LT07-705, Lonza, Basel, Switzerland)
was used for conﬁrming the cell cultures negative for
mycoplasma.
Antibodies, inhibitors, and growth factors
The antibodies used were as follows: mouse monoclonal
antibodies against ERBB2/HER2 (MA5-13105, Thermo
Fisher Scientiﬁc (Waltham, MA, USA) for IF, and NCL-L-
CB11; Leica Biosystems, Wetzlar, Germany), FGFR4 (sc-
136988, Santa Cruz Biotechnology, Dallas, TX, USA),
FLAG (9A3; 8146, Cell Signaling Technology, Beverly,
MA, USA), glyceraldehyde-3-phosphate dehydrogenase
(G8795; Merck, Darmstadt, Germany), MST1 (sc-100449,
Santa Cruz Biotechnology, for IF), phospho-tyrosine (05-
321, Merck), YAP/TAZ (63.7; sc-101199, Santa Cruz
Biotechnology), rabbit monoclonal antibodies against active
YAP (EPR19812; ab205270, Abcam, Cambridge, UK), and
MOB1 (13730 S), MST1 (D8B9Q; 14946), phospho-
MST1/2 (T183/180) (E7U1D; 49332), phospho-MOB1
(pT35) (D2F10; 8699), and phospho-tyrosine (8954, Mul-
tiMab) all from Cell Signaling Technology. Rabbit poly-
clonal antibodies against FGFR4 (sc-124; Santa Cruz),
phospho-FGFR4 (pY642; CSB-PA008250, Cusabio Tech-
nology, Houston, TX, USA) and phospho-FRS2-α (pY196;
3864), MST1 (3682), MST2 (3952), phospho-p44/42
MAPK (phospho-Erk1/2) (pT202/pY204; 9101), phospho-
AKT (pS473; 9271), phospho-MST1/2 (pT183/pT180;
3681), phospho-YAP (pS127; 4911) all from Cell Signaling
Technology, V5-tag (ab9116; Abcam), and horseradish
peroxidase–conjugated secondary antibodies (P044701 and
P044801, Dako, Santa Clara, CA, USA) for enhanced
chemiluminescence detection of immunoblots. Species-
matched Alexa Fluor conjugated secondary antibodies and
phalloidin (Life Technologies, Carlsbad, CA, USA) were
used for immunoﬂuorescence. FGFR4 inhibitor BLU9931
(S7819) [29] was purchased from Selleckchem (Munich,
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Germany), and MST1/2 inhibitor XMU-MP-1 (6482) [30]
from Tocris Bioscience (Bristol, UK). Okadaic acid
(10011490) was purchased from Cayman Chemical (Ann
Arbor, MI, USA). Recombinant human ﬁbroblast growth
factor 1 (GF002) and ﬁbroblast growth factor 2 (GF003)
were purchased from Merck.
cDNA constructs, small interfering RNAs, and short
hairpin RNAs
Flag epitope (N-terminal)-tagged MST1 and MST2 in the
p3FLAG-CMV-10wt (Merck) expression vectors have
been described previously [31]. MST1-Y433F mutant was
generated by site-directed mutagenesis. FGFR4 and its
kinase activity-deﬁcient mutant (K503M) were cloned into
pcDNA3.1/V5-His vector, and the expression vector for
FGFR4 G388 variant was generated from R388 variant by
site-directed mutagenesis [32, 33]. Pools of four siRNAs
against human STK3 (MST2; L-004874), STK4 (MST1; L-
004157), FGFR4 (L-003134), and nontargeting control
siRNA (D-001206-14) (all from Dharmacon/Horizon
Discovery, Cambridge, UK) were used; and for FGFR4
also SI02665306 (siFGFR4_6), SI00031360 (siFGFR4_2)
and SI00031374 (siFGFR4_4) from Qiagen (Hilden,
Germany).
Short hairpin RNA (shRNA) targeted against FGFR4
(TRCN0000000628 and TRCN0000199510; or nontarget-
ing scrambled shRNA were used (Dharmacon/Horizon
Discovery). The packaging plasmid (pCMVdr8.74), envel-
ope plasmid (pMD2-VSVG), and FGFR4 or scrambled
shRNA in pLKO.1 vector were co-transfected into 293FT
producer cells using Lipofectamine 2000 reagent (Invitro-
gen). Complete breast carcinoma cell growth medium was
changed on 293FT cells 24 h after transfection. The viral
supernatants were collected after 48 h, passed through a
0.45-µm ﬁlter, and incubated with human breast carcinoma
cells. After 16 h of infection, the supernatants were replaced
with complete media followed by puromycin (2–5 µg/ml)
selection of the transduced cells [34].
Cell transfections, sphere preparation, and
treatments
The cells were transfected with expression vectors using
FuGENE HD (Promega, Madison, WI) and siRNAs using
Lipofectamine 2000 (Invitrogen), Interferin (Polyplus-
transfection SA, Illkirch-Graffenstaden, France) or Dhar-
mafect 1 or Dharmafect 2 (Dharmacon/Horizon Discovery).
For 2D immunoﬂuorescence, cells were seeded on mono-
meric collagen type I-coated (50 μg/ml, C7661, Merck)
coverslips, ﬁxed in 4% paraformaldehyde (pH 7.5), and
stained as previously described [35], and mounted in
Vectashield with (DAPI; Vector Laboratories, Burlingame,
CA, USA).
Spheres of 24,000 cells were allowed to form under non-
adherent conditions in agarose-coated 96-well plates in cell
culture media supplemented with 0.2 mg/ml Matrigel
(growth factor reduced, 354230; Corning/Merck), or on
ultra-low attachment 96-well plate (Corning® Costar®
CLS7007, Merck) without Matrigel, and cultured for 2–
8 days [36]. The spheres were cultured in the indicated
serum concentrations, or serum-starved for 16 h before
inhibitor treatment, followed by lysis with radio-
immunoprecipitation assay (RIPA) buffer. For immuno-
ﬂuorescence, the spheres were ﬁxed in 4%
paraformaldehyde (pH 7.5), post-ﬁxed in ice-cold acetone-
methanol (1:1) solution, incubated in blocking buffer (5%
bovine serum albumin (BSA), 0.1% Triton X-100 in PBS)
and stained for MST1 and YAP. Nuclei were visualized
with Hoechst 33342 stain (Thermo Fisher Scientiﬁc). The
spheres were mounted on glass slides in Vectashield
(Vector Laboratories). At least two independent cultures per
stable lentiviral shRNA transduction were analyzed for
MST1.
Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting were performed
as described previously [37]. Cells were lysed with RIPA
buffer (50 mM Tris-HCl pH 7.4, 150mM NaCl, 1% Igepal
CA-630, 0.5% sodiumdeoxycholate) containing Complete
protease inhibitor cocktail (Merck), 2 mM Na3VO4, and 2 mM
NaF and cleared by centifugation. For immunoprecipitation
from the soluble cell lysates, the samples were further
diluted 1:3 with Triton lysis buffer (50 mM Tris-HCl pH 8.0,
150mM NaCl, 1% Triton X-100, 5 mM CaCl2, 0.02% NaN3)
containing Complete protease inhibitor cocktail, 2 mM
Na3VO4, and 2 mM NaF and pre-cleared with protein A
Sepharose. MST1 or MST2 were immunoprecipitated from
cleared supernatants with EZview Red anti-FLAG M2
Afﬁnity Gel (Merck) for 4 h at 4 °C. After washing with
Triton lysis buffer, bound proteins were eluted with reducing
sodium dodecyl sulphate (SDS-PAGE) sample buffer
(0.12 M Tris-HCl pH 6.8, 0.02% bromophenol blue, 4%
SDS, 50% glycerol, 0.1 M dithiotreitol). Protein concentra-
tions were determined with BCA Protein Assay Kit (23225,
Thermo Fischer Scientiﬁc), and equal protein amounts (µg)
were separated by SDS-PAGE and transferred to nitro-
clellulose membranes for subsequent detection with primary
antibodies and matched secondary antibodies conjugated to
horseradish peroxidase. All immunoblots are representative
images of experiments repeated independently at least three
times; except for Figs. 5b, e and 6a, b, where the experi-
ments were repeated twice.
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Mass spectrometry analysis of phosphorylation sites
All buffers of immunoprecipitation and elution procedures
were supplemented with Complete protease inhibitor
cocktail and PhosSTOP phosphatase inhibitor tablets
(Merck). After the general immunoprecipitation washes, the
anti-FLAG afﬁnity gel was washed with pre-urea wash
buffer (50 mM Tris pH 8.5, 1 mM ethylene glycol-bis(β-
aminoethyl ether (EGTA), 75 mM KCl) before elution with
urea buffer (6 M urea, 20 mM Tris pH 7.5, 100 mM sodium
chloride). Elution cycles were repeated three times for 30
min each at room temperature with agitation. Proteins in
eluates were reduced with (tris(2-carboxyethyl)phosphine),
alkylated with iodoacetamide, and trypsin digested with
Sequencing Grade Modiﬁed Trypsin (Promega). Phospho-
peptide enrichment was performed using immobilized metal
ion afﬁnity chromatography with titanium (IV) ion (Ti4
+-IMAC). IMAC material was prepared and used essen-
tially as described [38]. The liquid chromatography with
tandem mass spectrometry (LC-MS/MS) analysis was per-
formed using a Q Exactive ESI-quadrupole-orbitrap mass
spectrometer coupled to an EASY-nLC 1000 nanoﬂow LC
(Thermo Fisher Scientiﬁc), using Xcalibur version
3.1.66.10 (Thermo Fisher Scientiﬁc). The phoshopeptide
sample was loaded from an autosampler into a C18-packed
precolumn (Acclaim PepMap™100; 100 μm×2 cm, 3 μm,
100 Å, Thermo Fisher Scientiﬁc) in buffer A (1 % acet-
onitrile, 0.1 %, formic acid). Peptides were transferred
onward to a C18-packed analytical column (Acclaim Pep-
Map™100 75 μm×15 cm, 2 μm, 100 Å, Thermo Fisher
Scientiﬁc) and separated with 60-minute linear gradient
from 5 to 35 % of buffer B (98 % acetonitrile, 0.1% formic
acid) at the ﬂow rate of 300 nl/minute. The MS analysis was
performed in data-dependent acquisition in positive ion
mode. MS spectra were acquired from m/z 300 to m/z 2000
with a resolution of 70,000 with Full AGC target value of
3,000,000 ions, and a maximal injection time of 120 ms, in
proﬁle mode. The ten most abundant ions with charge states
from 2+ to 7+were selected for subsequent fragmentation
(higher energy collisional dissociation, HCD) and MS/MS
spectra were acquired with a resolution of 17,500 with AGC
target value of 5000, a maximal injection time of 120 ms,
and the lowest mass ﬁxed at m/z 120, in centroid mode.
Dynamic exclusion duration was 30 s. Raw data ﬁles were
analyzed with the Proteome Discoverer software version 1.3
(Thermo Fisher Scientiﬁc) connected a Sequest search
engine version 28.0 (Thermo Fisher Scientiﬁc) against the
human component of the Uniprot Database (version
07_2017). Carbamidomethylation (+57.021 Da) of cysteine
residues was used as static modiﬁcation. Phosphorylation of
Ser/Thr/Tyr (+79.966 Da) and oxidation (+15.994 Da) of
methionine was used as dynamic modiﬁcation. Precursor
mass tolerance and fragment mass tolerance were set to < 15
ppm and 0.05 Da, respectively. A maximum of two missed
cleavages was allowed. The software phosphoRS [39] was
used to calculate the indvidual site probabilities for phos-
phorylated peptides.
Flow cytometry analysis of apoptosis
The proportions of apoptotic cells were determined by ﬂow
cytometry for annexin V and propidium iodide (PI) binding
[40]. Stable shScr or shFGFR4 transduced MDA-MB-453
cells were transfected with siRNAs. After 72 h the cells,
including ﬂoating cells in the medium, were collected by
trypsinization, washed and labeled with annexin V-Alexa
Fluor488 (A13201; Life Technologies) diluted into binding
buffer (10 mM HEPES—140 mM sodium chloride—2.5 mM
calcium chloride) for 15 min at room temperature. Cells
were suspended into binding buffer, stained with 1 µg/ml PI
(P3566, Life Technologies), and analyzed with BD Accuri
C6 ﬂow cytometer (BD Biosciences, San Jose, CA, USA).
Gating and data analysis were performed using FlowJo
v10.1 software (Tree Star Inc., Ashland, OR, USA). Geo-
metric mean ﬂuorescence of annexin V binding (FL1-A)
alone or combined with PI binding (FL3-A) was quantiﬁed.
Experiments were repeated three times.
In vitro kinase assays
MST1 Kinase Enzyme System, including Axltide peptide
(KKSRGDYMTMQIG) as MST1 substrate, with ADP-Glo
reagent (V4153, Promega) was used according to manu-
facturer’s instructions to measure ADP production in kinase
reactions. The reaction buffer (40 mM Tris, pH 7.5—20 mM
magnesium chloride—0.1 mg/ml BSA—50 μM dithiotreitol)
was supplemented with 2.5 µM manganese chloride to
enhance tyrosine kinase activity. Recombinant MST1
kinase (3 ng) was incubated with 0–10 ng of recombinant
kinase domain of FGFR4 (P3054, Thermo Fisher Scien-
tiﬁc), together with 1 µM XMU-MP-1 (MST1/2 inhibitor) as
an assay control. The kinase reactions with ﬁnal 50 μM ATP
concentration were incubated at room temperature for 1 h
on ProxiPlate (PerkinElmer, Waltham, MA, USA), ADP-
Glo reagent was added for 40 min, followed by addition of
kinase detection reagent for 30 min’ incubation before
reading the luminescence with EnSight plate reader (Per-
kinElmer). Experiment was repeated three times. For
in vitro kinase assay detection by immunoblotting, 40 ng of
MST1 kinase and 0–100 ng recombinant kinase domain of
FGFR4 were incubated together for 30 min at 30 °C, with or
without 1 µM XMU-MP-1 or 100 nM BLU9931 (FGFR4
inhibitor) using the abovementioned buffers and
MST1 substrate. Proteins in the kinase reaction were
denatured and reduced using SDS-PAGE sample buffer
(0.12 M Tris-HCl pH 6.8, 0.02% bromophenol blue, 4%
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SDS, 50% glycerol) supplemented with 10% (v/v) β-mer-
captoethanol, and subjected to immunoblotting for detecting
phosphorylation of MST1 and FGFR4. Experiment was
repeated two times.
Drug sensitivity and resistance testing and data
processing
Compounds (from FIMM Oncology set; https://www.ﬁmm.
ﬁ/en/services/technology-centre/htb/equipment-and-libra
ries/chemical-libraries) and viability controls (DMSO,
100 µM benzethonium chloride) were predispensed on tissue
culture treated 384-well plates (Corning, NY, USA). Each
compound was plated as singlicate in ﬁve concentrations
spanning a 10,000-fold concentration range (10-fold dilu-
tion). Assay ready plates were stored in pressurized Stor-
agePods (Roylan Developments, Surrey, UK) under inert
atmosphere until used. Using a MultiDrop Combi (Thermo
Scientiﬁc) 5 µL media with or without 500 nM BLU9931
(5× concentration) was ﬁrst dispensed into assay ready
plates and centrifuged brieﬂy. Twenty microliters of a
single-cell suspension (2000 cells) was then seeded using
MultiDrop Combi peristaltic pump to the plates, which were
centrifuged brieﬂy and transferred to an incubator (37 °C
and 5% CO2). As a surrogate for cell viability, cellular ATP
levels were assessed 72 h after plating using CellTiterGlo
2.0 (Promega) with detection on an EnSight plate reader
(PerkinElmer). Using in house software, data from the plate
reader were normalized per plate to percent viability using
values from control wells. Concentration-response curves
were ﬁtted to percent viability values using a four-parameter
logistic model, and processed further to a sensitivity metric
(drug sensitivity score; DSS) using a weighted area-under-
the-curve calculation [41]. DSS for each drug was com-
pared between conditions tested.
Real-time quantitative PCR (qPCR)
RNA was extracted with an RNeasy Plus Mini kit (Qiagen),
coupled with RNeasy MinElute columns (Qiagen) for small
amount of starting material from non-adherent sphere cul-
tures, followed by reverse transcription with Maxima First
Strand cDNA Synthesis Kit (Thermo Scientiﬁc). mRNA
expression was quantiﬁed using TaqMan Fast Advanced
Master Mix (Applied Biosystems, Foster City, CA, USA),
and validated primers (connective tissue growth factor
(CTGF), Hs01026927_g1; cysteine rich angiogenic inducer
61 (CYR61), Hs_00998500_g1; ankyrin repeat domain 1
(ANKRD1), Hs_00173317_m1; TATA-binding protein
(TBP) Hs99999910_m1; Applied Biosystems). The
expression was normalized with TBP mRNA expression.
Two independent RNA extractions were performed, each
analyzed in triplicates by qPCR.
Fibrin-embedded 3D cell cultures for
immunohistochemisrty
Preparation of cross-linked ﬁbrin gels was perfomed
essentially as described [42], and 17,250 cells were sus-
pended into 75 µl of ﬁbrin gel and casted to 96-well plate.
Matrix-embedded single cells were cultured with complete
growth medium atop for 7–8 days before ﬁrst treatment
with 100 nM BLU9931 and/or 30 ng/ml FGF1. Inhibitor
treatment was added again 72 h later, and cells were ﬁxed
after 13–14 days of culture with 4% paraformaldehyde in
PBS for 4 h at room temperature. Fibrin gels were dehy-
drated, parafﬁn-embedded for sectioning, and subjected
immunohistochemistry essentially as described [43]. Sec-
tions were subjected to heat-induced antigen retrieval in
Tris-ethylenediaminetetraacetic acid, pH 9.0 (for Ki67
antibody, ACK02, Leica Biosystems), or in sodium citrate,
pH 6.0 (for Bax antibody, HPA027878, Sigma-Aldrich).
Sections were subsequently incubated in 3% (v/v) hydrogen
peroxide for 10 min. For antigen detection, tyramide signal
ampliﬁcation (TSA™, PerkinElmer) technology, followed
by incubation with 3‐amino‐9‐ethyl‐carbazole solution,
were used according to manufacturer’s instructions. Total
30 colonies from two replicate samples were quantiﬁed for
positively stained vs. total number of cells.
Imaging and image quantiﬁcation
Fluorescence images were obtained using an AxioImager.
Z2 upright epiﬂuorescence microscope with Plan-
Apochromat × 20/0.8 NA dry or × 40/1.4 NA oil objec-
tive. In addition, an LSM 780 confocal microscope with
Plan-Neoﬂuar × 40/1.3 NA oil objective was used (all from
Carl Zeiss, Oberkochen, Germany). Brightness and contrast
were linearly adjusted using ZEN 2012 (blue edition; Carl
Zeiss). Single optical sections or a combination of two serial
optical sections were used for image display.
The MST1 and YAP-stained sphere images were ana-
lyzed using Anima [44]. Cell nuclei were detected from
4′,6-diamidino-2-phenylindole (DAPI) channel by ﬁrst
normalizing images with adaptive histogram equalization,
and then using the Shape ﬁltering segmentation method
found in Anima. The MST1 or YAP signal intensity values
were measured from the nucleus area and from a ring
around the nucleus representing the cytoplasm. The ring
width was determined as 50% of the radius of the nucleus.
The nucleus/cytoplasm intensity ratio was calculated by
dividing nuclear intensity with cytoplasmic intensity for
each nucleus, and then calculating a median value for each
image.
Image quantiﬁcations of western blotting were performed
by processing all obtained micrographs with ImageJ
software.
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Statistics
All numerical values represent mean ± SD or SEM as
indicated in ﬁgure legends. Statistical signiﬁcance was
determined using two-tailed Student's t tests for analysis of
apoptosis, quantiﬁcations of immunoblots and immunohis-
tochemistry. The Kolmogorov–Smirnov test was used for
computerized image analysis data on MST1 and YAP-
stained sphere images.
Results
FGFR4 tyrosine phosphorylates Hippo pathway
proteins in vitro and in cells
To systematically screen for substrates serving as down-
stream effectors of FGFR4, we used recombinant FGFR4
kinase domain to assess in vitro phosphorylation of 9483
human recombinant proteins (Fig. 1a, Table S1, Z-score
ranking). Unexpectedly, the top ﬁve substrates included
four Hippo tumor suppressor pathway proteins; MST2
(STK3), protein kinase C iota (PRKCI), casein kinase I delta
(CSNK1D) [45], and MST1 (STK4) (Fig. 1b; STK3 and
PRKCI identiﬁed as two splice variants), suggesting that
FGFR4 can directly phosphorylate the Hippo serine/threo-
nine kinase pathway proteins (Fig. 1b). To validate this
activity, MST1/2 were immunoprecipitated from COS-1
cells after transfection of MST1 and MST2 alone or in
combination with FGFR4-G (G388) or the cancer-
associated FGFR4-R (R388) variant. Notably, both var-
iants induced MST1 and MST2 tyrosine phosphorylation,
revealing these Hippo kinases as novel FGFR4 substrates
(Fig. 1c). Importantly, the FGFR4-R-mediated MST1/2
phoshorylation was not detected with kinase activity-
deﬁcient FGFR4-R-KD (Fig. 1d).
To identify the FGFR4 phosphorylated tyrosine residue
(s), immunoprecipitated MST1 was subjected to mass
spectrometry (Fig. S1A). Notably, MST1 from FGFR4
expressing cells was phosphorylated at Y433, whereas
MST1 from cells with inactive FGFR4 KD lacked detect-
able tyrosine phosphorylation (Fig. 1e, Table 1). In
Fig. 1 FGFR4 substrate screen
identiﬁes tyrosine-
phosphorylated Hippo pathway
proteins including MST1/2.
a Scheme of the substrate screen
with recombinant FGFR4 kinase
domain. b Top 10 FGFR4
substrates ranked by the Z-score
include Hippo pathway
-associated proteins (yellow).
See Table S1 for the full
substrate list. c, d MST1/2 are
tyrosine phosphorylated by
FGFR4 in COS-1 cells. Flag-
tagged MST1/2 were
immunoprecipitated after
transfection of MST1 and MST2
alone or in combination with
FGFR4 G388 (G), or R388 (R)
kinase (wt), or kinase-dead (KD)
variants, and detected by
immunoblotting. e MST1
immunoprecipitates from COS-1
cells co-transfected with FGFR4
(R)-wt or FGFR4 (R)-KD (See
Fig. S1A) were trypsin digested
and subjected to phoshopeptide
enrichment prior to LC-MS/MS
analysis (N= 3) that identiﬁed
phosphorylated Y433 (red) on
MST1 only with FGFR4 (R)-wt,
and phosphorylated S410
(green) only with FGFR4 (R)-
KD
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addition, an uncharacterized MST1 phosphorylation at S410
near the pY433-site was detected only with kinase-deﬁcient
FGFR4 (Fig. 1e, Table 1), whereas MST1 S320 and T177
were phosphorylated in both samples independently of
FGFR4 activity (Table 1).
FGFR4 is overexpressed in HER2+, MST1/2low breast
cancer cells, and correlates with adverse outcome in
HER2-enriched breast cancer patients
To understand the signiﬁcance of the identiﬁed novel
FGFR4 activity, and to establish relevant cell models, we
ﬁrst analyzed FGFR4 expression using TCGA by
cBioPortal for Cancer Genomics [46, 47]. In breast cancer,
FGFR4 was overexpressed in 33% of HER2-enriched
tumors (PAM50 classiﬁed, n= 58) [48], and signiﬁcantly
associated with poorer overall survival compared with the
non-overexpressing group (Fig. S1B; P= 0.044; FGFR4
overexpression in 4% of all breast cancers; n= 825 [4]).
Consistently, MDA-MB-453 (ER−, PR−, HER2+) as well
as ZR-75.1 and BT474 (ER+, PR+/−, HER2+) breast cancer
cells expressed FGFR4, whereas both FGFR4 and HER2
were low in MCF7 and T47D (ER+, PR+/−, HER2−), and
negligible in triple-negative (ER−, PR−, HER2−) cells
(Fig. 2a, S1C) [49]. By immunoﬂuorescence, strong intra-
cellular and cell surface FGFR4 was associated with cell
Table 1 List of MST1 phoshopeptides identiﬁed by mass spectrometry
Co-transfected kinase Protein Phospho-residue Peptide sequence Peptide FDR phosphoRS site
probabilities (%)
FGFR4/R-wt MST1_Q13043 Y(433) IPQDGDYEFLK <0.01 100
MST1_Q13043 S(320) EVDQDDEENSEEDEMDSGTMVR <0.01 100
MST1_Q13043 S(410) EKENQINSFGK N/A 0
MST1_Q13043 T(177) LADFGVAGQLTDTMAK <0.01 99.9
FGFR4/R-KD MST1_Q13043 Y(433) IPQDGDYEFLK N/A 0
MST1_Q13043 S(320) EVDQDDEENSEEDEMDSGTMVR <0.01 100
MST1_Q13043 S(410) EKENQINSFGK <0.01 100
MST1_Q13043 T(177) LADFGVAGQLTDTMAK <0.01 100
Fig. 2 FGFR4 is overexpressed
in HER2+, MST1/2low breast
cancer cells. a, b FGFR4 and
HER2 expression in luminal
MDA-MB-453, ZR-75.1, and
BT474, MCF7, and T47D, and
ﬁve triple-negative breast cancer
cell lines by a immunoblotting
and b immunoﬂuorescence.
Scale bar 20 μm. c MST1,
MST2, and YAP/TAZ
expression in these cell lines,
detected by immunoblotting
(N= 3)
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surface HER2 in MDA-MB-453, which harbor an activating
FGFR4 mutation [50, 51], and in ZR-75.1, rendering these
cells suitable endogenous models for FGFR4 function
(Fig. 2b).
Among these cell lines, MST1 was lowest in ZR-75.1,
MCF7, and MDA-MB-453 (Fig. 2c). Moreover, FGFR4+
ZR-75.1 and MDA-MB-453 expressed low levels of
MST2 and TAZ, whereas TAZ was prominent in triple-
negative, and YAP in all except ZR-75.1 and MCF7 cells
(Fig. 2c).
Endogenous FGFR4 inhibits MST1/2 activation and
cleavage
To test if FGFR4 regulates the tumor-suppressive MST1/2
kinases, MDA-MB-453 cells were transfected with siRNAs
speciﬁc for FGFR4, MST1, and MST2. In control cells,
weak protein bands corresponding to full length and cleaved
MST1/2 were detected with antibodies against active,
pT183/180-autophosphorylated MST1/2 (Fig. 3a). Mark-
edly, FGFR4 knockdown enhanced the cleaved active
pMST1/2 (Fig. 3a, arrowhead). Total MST1, present in
control cells as full-length protein, became detectable as an
additional 36/37 kDa form after FGFR4 knockdown
(Fig. 3b; see N-terminal form similar to the caspase-cleaved
MST1/N; [19, 23]). MST2 instead was detected as full-
length protein (Fig. 3b). Importantly, after lentiviral
FGFR4 silencing (shFGFR4), ectopic FGFR4 (R388 and
G388 variant) expression rescued the cleaved MST1 and
pMST1/2 back to the low levels of controls (shScr) (Fig. 3c,
S2A). In contrast, cancer-associated FGFR4-R slightly
induced MST2 cleavage (Fig. 3c; FGFR4-G/R vary in sta-
bility and signal output; endogenous FGFR4 in MDA-MB-
453 contains G388R and the activating Y367C alterations
[12, 33, 50–52]). In MDA-MB-231, FGFR4-R, and -G also
decreased the cleaved MST1 (Fig. S2B), and even more
efﬁciently upon FGF1 and FGF2 stimulation as shown in
FGFR4-R cells (Fig. S2C).
Coincident with increased MST1/2 cleavage and acti-
vation, FGFR4 knockdown resulted in signiﬁcantly
increased threonine (T35) phosphorylation of the MST1/
2 substrate MOB1 in MDA-MB-453 (Fig. 3d; P < 0.05;
[53]). In ZR-75.1, FGFR4 silencing likewise enhanced
pMOB1 (Fig. 3d; P < 0.05) and pMST1/2 (Fig. 3e). How-
ever, this was coupled with increased full-length and
cleaved MST2, whereas cleaved MST1 was less enhanced
(Fig. 3e). To clarify distinct MST contributions to FGFR4
depletion-induced pMST1/2, FGFR4 was silenced alone
and in combination with MST1 or MST2 in MDA-MB-453.
In subconﬂuent low-serum cultures with prominent activa-
tion of MST1/N upon FGFR4 depletion, partial MST1
knockdown increased pMOB1 with and without FGFR4
(Fig. 3f; note that serum suppresses distinctively MST2
[54]). Instead, MST2 double knockdown with FGFR4
blocked the enhanced threonine phosphorylation of MOB1
and cleaved MST1/2, while even increasing MST1 cleavage
(Fig. 3f). Thus, MST1/2 were interregulated, and MST2
was essential for the induction of active MST1/N and
pMOB1 after FGFR4 depletion.
As MDA-MB-453 and ZR-75.1 both contain the
cancer-associated FGFR4-R388 (MDA-MB-453, homo-
zygous; ZR-75.1, heterozygous), we further silenced
FGFR4 in BT474 homozygous for FGFR4 G388, which
increased MST1/N as well as full-length MST1/2
(Fig. 3g), indicating that both FGFR4 variants can sup-
press MST1.
FGFR4 counteracts MST1/2-mediated apoptosis
MST1/2 activation by T183/180 autophosphorylation and
cleavage is associated with apoptosis [19]. To investigate if
FGFR4 alters the pro-apoptotic MST1/2 function, MDA-
MB-453 cells were transduced with shScr and shFGFR4,
followed by transfection of FGFR4, MST1, and
MST2 siRNAs. Apoptosis was measured by annexin V and
PI binding with ﬂow cytometry using two gating strategies:
P1 (smaller) and P2 (larger) cells for early apoptosis by
annexin V (Fig. 4a), and the whole-cell population for
combined early and late apoptotic cells by double positivity
(Fig. 4b, S3B). Stable FGFR4 silencing signiﬁcantly
increased apoptosis relative to control (Fig. 4a, b, S3A; P ≤
0.02). Similarly, FGFR4 siRNAs increased apoptosis in
shScr cells (Fig. 4a, b; P < 0.001). MST1 or MST2
knockdown did not decrease apoptosis in shScr cells with
high endogenous FGFR4, and FGFR4 siRNAs did not
further increase apoptosis in shFGFR4 cells (Fig. 4a, b).
Notably, the apoptosis induction by stable FGFR4 silencing
was rescued close to the low level of shScr cell apoptosis by
MST1 (P= 0.02) or MST2 (P= 0.003) knockdown in
shFGFR4 cells (Fig. 4a, b, and S3B), suggesting that MST1
and MST2 act together to induce apoptosis, unless atte-
nuated by FGFR4 in MDA-MB-453.
FGFR4 silencing increases MST1/2 activation and
MST1 nuclear translocation in cancer cell spheres
Three-dimensional (3D) cell spheres recapitulate the cell-
cell contacts and dimensionality of in vivo tumors. To
investigate MST1/2 regulation in 3D, MDA-MB-453 cells
were cultured in non-adherent conditions for sphere for-
mation. In complete medium, control and FGFR4 knock-
down spheres had minor differences in MST1/2 and MOB1
total protein and phoshorylation (Fig. 5a; 10% fetal bovine
serum; FBS). Markedly, FGFR4 depletion in low serum
increased MST1/2 cleavage (total and pT183/180) and
pMOB1 (Fig. 5a; 2% FBS). Treatment with FGFR4-speciﬁc
2584 S. P. Turunen et al.
Fig. 3 FGFR4 suppresses MST1/2 activation and cleavage in HER2+
breast cancer cells. a, b MDA-MB-453 cells transfected with indicated
siRNAs were subjected to immunoblotting for a T183/180 phos-
phorylated MST1/2, and b MST1 and MST2. Note cleaved ~ 37 kDa
MST1/N in FGFR4 knockdown cells (arrowhead). Thin gray line
indicates cropping to leave out irrelevant sample lane; see uncropped
immunoblots in Fig. S8. c MDA-MB-453 cells transduced with indi-
cated shRNAs were transfected with siScr or siFGFR4 siRNA to
3’UTR before transfection of mock or FGFR4 (R) or (G) over-
expression plasmid for a rescue experiment. Lysates were subjected to
immunoblotting as indicated. Brackets indicate the cleaved MST1 and
MST2 fragments. See Fig. S2A for phopsho-FRS2α and short expo-
sure of MST1. d MDA-MB-453 and ZR-75.1 cells were transduced
with indicated si/shRNAs; upper, indicated immunoblots of lysates;
lower, quantiﬁcation of pMOB1/MOB1 ratio, N= 3, mean ± SEM;
*P < 0.05. For MST1/2 knockdown e ZR-75.1 and f MDA-MB-453
were transduced with shRNAs followed by transfection with siRNAs
as indicated, and g BT474 cells were transfected with indicated siR-
NAs, and subjected to immunoblotting for pT183/180 MST1/2,
MST1, MST2, and pMOB1 as indicated (in e arrowhead points to a
full-length, bracket to the cleaved MST2) a–g. N= 3 independent
repeats for all; except N= 2 in f and g
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inhibitor BLU9931 [29] for 15 min likewise increased
pMST1/2 (Fig. 5b). During this short FGFR4 inhibition,
pFRS2α was diminished, whereas pAKT and pERK
remained less affected (Fig. 5b), suggesting that MST1/2
activation upon FGFR4 inhibition is an early event in the
apoptosis induction. By immunoﬂuorescence, both MDA-
MB-453 and ZR-75.1 spheres had low nuclear and cyto-
plasmic MST1, whereas FGFR4 silencing speciﬁcally
increased punctate, nuclear MST1, signiﬁcantly increasing
the nucleus/cytoplasm ratio (Fig. 5c, d, S3C), thus sug-
gesting that FGFR4 inhibits MST1/2 activation and MST1/
N nuclear localization to counteract apoptosis.
To further examine the FGFR4-dependent regulation and
individual MST1 and MST2 functions, all three genes were
silenced in distinct combinations in 3D. As expected,
FGFR4 knockdown increased the cleaved pMST1/2 and
pMOB1, which response was prevented by MST1 depletion
in MDA-MB-453 (Fig. 5e). After MST2 silencing alone or
in combinations with FGFR4 and/or MST1, the higher
molecular weight pMST1/2 forms were reduced. The
cleaved pMST1/2, although reduced, remained detectable
after combined MST2 and FGFR4 silencing, suggesting
that it corresponds to MST1/N (Fig. 5e). However, com-
bined knockdown of FGFR4 with MST1, MST2 or both the
MSTs, prevented pMOB1 induction (Fig. 5e). In ZR-75.1
with MST2-dominated response to FGFR4 knockdown (see
Fig. 3e), FGFR4 and/or MST1 knockdown instead
enhanced pMOB1, whereas MST2 and FGFR4 double
depletion fully prevented this induction (Fig. S4A). There-
fore, MST1 and MST2 were cooperatively activated upon
FGFR4 depletion, leading to context-dependent dominance
of partially competing outcomes of MST2-dependent
MST1/N activation or (cytoplasmic) MST2-MOB1 axis.
Mutation of MST1-pY433-site restores MST1/2
activation in FGFR4 expressing cells
To examine the effects of the identiﬁed FGFR4-dependent
tyrosine phosphorylation in MST1, wild-type MST1 and the
pY433-site mutant MST1-Y/F were overexpressed alone
and in combination with FGFR4-R in MDA-MB-231 cells.
Although weak autoactivated pMST1/2 was detected in
cells overexpressing MST1 (wild-type or mutant) alone or
MST1 (wild-type) and FGFR4-R, co-expression of MST1-
Y433F and FGFR4 resulted in prominent pMST1/2 autop-
hosphorylation (Fig. 6a and Fig. S4B). Coincidentally, the
downstream pMOB1 was increased relative to total MOB1
(Fig. 6a). Since inactivating NF2 mutation in MDA-MB-
231 can affect MST1/2 activation [55], we next transfected
T47D cells to express FGFR4-R and MST1 (wild-type or
Y433F). In these cells, MST1 remained inactive as reﬂected
by unchanged pMST1/2 and pMOB1, except if okadaic
acid, known to enhance pMST1/2 by PP2A phosphatase
inhibition [56], was added (Fig. S4C). This treatment dra-
matically increased pMOB1 along with pMST1/2 detection
as a doublet in mock and MST1-overexpressing cells
(Fig. 6b, S4C). Notably, FGFR4 suppressed pMST1/2 in
okadaic acid-treated mock and wild-type MST1 cells,
whereas pMST1/2 and pMOB1 were increased after MST1-
Y433F and FGFR4 co-expression (Fig. 6b, S4C).
In these okadaic acid-treated cells, MST1 or MST2
knockdown suppressed pMOB1, MST2 depletion being most
Fig. 4 FGFR4 counteracts MST1/2-mediated apoptosis. MDA-MB-
453 cells transduced with shScr or shFGFR4 shRNAs were transfected
with siRNA pools speciﬁc for FGFR4, MST1 or MST2, and analyzed
for annexin V and propidium iodide (PI) binding by ﬂow cytometry
using two different gating strategies for data visualization. a Gating to
populations P1 (smaller) and P2 (larger), and annexin V binding
(FL1-A) histograms as a marker for early apoptotic cells. b Quantiﬁ-
cation (% of total, 100,000 events) of apoptosis based on double-
positive (annexin V+ PI) cells, including both early and late apoptotic
stages. See Fig. S3B for representative contour plots and quadrant
gating. Mean ± SD of triplicates shown, **P < 0.01; (repeated three
times; N= 3). FSC-A; forward scatter, and SSC-A; side scatter
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effective, and decreasing also pMST1/2 doublet (Fig. 6c).
Strikingly, MST2 knockdown also blocked the MST1-
Y433F-mediated pMST1/2 induction (Fig. 6c). After MST2
depletion, MST1-Y433F even reduced pMOB1, which effect
was reverted by FGFR4 (Fig. 6c). Considering such MST2-
dependence of FGFR4-mediated MST1 regulation, suggestive
of key changes in MST1/2 heterodimer interactions and
activity, we tested if FGFR4 can directly alter MST1 activity.
The recombinant MST1 activity, measured as ADP genera-
tion in vitro, was not altered by recombinant FGFR4, while
being inhibited by MST1 inhibitor XMU-MP-1 [30] (Fig.
S5A, B). Altogether, this is consistent with mutually com-
petitive MST2 cytoplasmic functions reﬂected by pMOB1,
and pro-apoptotic MST1/2 heterotypic activation, whereby
speciﬁcally the MST1/2 activation is suppressed by FGFR4-
dependent MST1-Y433 phosphorylation.
Regulation of YAP differs from pro-apoptotic MST1/
2 activation
We next analyzed protein alterations and target gene
transcription of the canonical Hippo pathway effector
YAP, to test if FGFR4 affects cytoplasmic MST1/2 sig-
naling [18, 19]. The nuclear/cytoplasmic YAP ratio
remained essentially unaltered in 3D cell spheres (Fig.
S6A). However, YAP localization shifted from irregular
to more polarized and membrane-proximal pattern after
FGFR4 silencing in MDA-MB-453 (Fig. S6B). This
coincided with subtle alterations in inactive (pS127-
YAP), total, or active (non-pS127) YAP (Fig. S6C, D),
without signiﬁcant changes in mRNAs for the canonical
YAP target genes CTGF, CYR61, and ANKRD1 (Fig.
S6E). In ZR-75.1, FGFR4 depletion enhanced inactive/
Fig. 5 FGFR4 suppresses MST1/2 activation and nuclear localization
in cancer cell spheres. a shScr and shFGFR4 MDA-MB-453 cell
spheres were cultured under non-adherent conditions (10% or 2%
FBS), and subjected to immunoblotting. Arrowhead; cleaved
N-terminal MST1/2 (in 2% FBS), brackets highlight the fragments of
autoactivated MST1/2. b MDA-MB-453 cell spheres were treated
with 100 nM BLU9931 for 15 min, and subjected to immunoblotting. c,
d shScr and shFGFR4 MDA-MB-453 and ZR-75.1 spheres were
analyzed for MST1 expression by c immunoﬂuorescence, and dMST1
nuclear/cytoplasmic ratio was quantiﬁed (n= 4–6 MDA-MB-453
spheres, ≥ 6 microscopic ﬁelds/sphere; n= 2–3 ZR-75.1 spheres, ≥ 8
microscopic ﬁelds/ sphere; mean ± SEM of two independent experi-
ments. Scale bar 10 µm. e shScr and shFGFR4 MDA-MB-453 cells
were transfected with indicated siRNAs before sphere formation,
cultured under non-adherent conditions (1% FBS) for 48 h, and sub-
jected to immunoblotting
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total and decreased active YAP in more MST2-dependent
manner (Fig. S7A). Therefore, FGFR4 had variable
effects on YAP, which did not concur with the pro-
apoptotic pMST1/2 regulation.
Apoptosis evasion by FGFR4 encompasses co-
targetable vulnerabilities with mitochondrial
apoptosis pathway and HER2/EGFR, AKT, and
mTORC1 signaling axes
To consider the overall impact of FGFR4 in human breast
cancer, we systematically analyzed (phospho)protein
alterations in FGFR4-overexpressing human tumors using
TCGA reverse phase protein array (RPPA) data. Sig-
niﬁcantly, the pro-apoptotic protein BAX, DNA repair
protein RAD50, and YAP (pS127 and total) were down-
regulated, along with the strongest decrease in progesterone
receptor, in FGFR4-overexpressing tumors (Fig. 7a).
Moreover, FGFR4 overexpression correlated with increased
total and pY1248-HER2/ERBB2, pY1068-EGFR, and
pY1248-ERBB3, in conjunction with adverse patient out-
come (Fig. 7a, S7B; TCGA [4]).
To relate these alterations in human tumors to the
FGFR4-dependent apoptosis evasion, we further analyzed
how FGFR4 regulates the cell phenotype in 3D matrix-
embedded cultures. The actively growing Ki67-positive
FGFR4+ MDA-MB-453 cells responded to the speciﬁc
FGFR4 inhibitor BLU9931 treatment (100 nM) with a ten-
dency to reduced proliferation as assessed by Ki67-
positivity (Fig. 7b, c; P= 0.07). More strikingly, pro-
apoptotic BAX protein positivity coupled to apoptotic
membrane blebbing increased signiﬁcantly (Fig. 7b, d; P=
0.001). Untreated ZR-75.1 cells instead grew poorly, but
showed prominent Ki67-positive growth upon FGF1 treat-
ment, which was inhibited by BLU9931 (Fig. 7e, f; P=
0.01), whereas here the concomitant increase in BAX did
not reach signiﬁcance (Fig. 7e, g).
Considering these indications, further linking FGFR4 to
apoptosis evasion in human tumors and 3D cultures, we next
systematically interrogated the association of FGFR4 activity
with drug sensitivity and resistance, targeting clinically
actionable vulnerabilities of cancer cells. To this end, we
screened a comprehensive oncology library comprised of 527
approved and investigational drugs in combination with
BLU9931 in MDA-MB-453 cells. Consistent with known
signaling pathway crosstalk [57–59], these cells were rela-
tively sensitive to several (pan)-PI3K/mTOR and AKT inhi-
bitors, and to a few histone deacetylase (HDAC) inhibitors, as
assessed by DSS [36] (Table S2). Moreover, MDA-MB-453
showed distinctive sensitivity towards BET/bromodomain
inhibitors, which as with most drugs, was not further affected
by BLU9931 at the used concentration (100 nM; Table S2).
Markedly, combination treatment with BLU9931 in com-
prehensive drug testing sensitized the FGFR4 inhibitor-treated
cells to the modulators of mitochondrial apoptosis pathway,
BCL-XL inhibitor (A-1155463) and a SMAC mimetic/IAP
inhibitor (Birinapant) (Fig. 7h, Table S3). HER2/EGFR,
AKT, and mTORC1 inhibitors (rapalogs) likewise showed
better efﬁcacy in BLU9931 treated cells, and importantly,
compounds with same mechanism of action showed
Fig. 6 MST1-Y433F phosphosite mutant restores MST1/2 activation
in FGFR4 expressing cancer cells. a MDA-MB-231 cells co-
transfected with FGFR4 (R) and wild-type or phosphosite mutant
MST1-Y433F were subjected to immunoblotting as indicated. Ratio of
pMOB1/MOB1 is indicated below the immunoblot panel. b T47D
cells (co-)transfected with wild-type or MST1-Y433F alone or with
FGFR4 (R) were treated with 1 µM okadaic acid for 1 h before cell
lysis, and subjected to immunoblotting. See corresponding T47D
immunoblots without okadaic acid in Fig. S4C. c T47D cells with
indicated siRNAs, and (co-)transfected with wild-type or MST1-
Y433F alone or with FGFR4 (R) were treated with 1 µM okadaic acid
as above, and subjected to immunoblotting. a–c Brackets and arrow-
head indicate the activated pMST1/2 fragments. N= 2 independent
repeats
2588 S. P. Turunen et al.
comparable shift in DSSs (Fig. 7h, Table S3). Moreover,
MDA-MB-453 cells were sensitive to pan-FGFR inhibitor
(LY-2874455), whereas the cells treated with BLU9931 did
not respond to additional FGFR targeting over a broad con-
centration range (Fig. 7h, Table S3).
Discussion
Apoptosis evasion is one of the classical hallmarks of
cancer. Here, we identiﬁed the apoptosis-promoting
MST1/2 as unique FGFR4 substrates by an unbiased
Fig. 7 FGFR4 confers resistance to apoptotic modulators in compre-
hensive drug screen. a (Phospho)protein changes in TCGA RPPA data
[4] associated with FGFR4 upregulation in breast cancer, visualized
using cBioPortal (RPPA score change in breast cancer tumors with and
without alterations in FGFR4; (mean FGFR4 altered – mean FGFR4
unaltered) [46, 47]. The most signiﬁcantly up- and downregulated
proteins are highlighted (pink dots); ERBB2, alternative name of
HER2; PR, progesterone receptor. b–g Fibrin embedded single-cell
suspensions of b–d MDA-MB-453 and e–g ZR-75.1 cells were treated
with 100 nM BLU9931 and/or 30 ng/ml FGF1 over a 13–14-day cul-
ture, ﬁxed, embedded into parafﬁn for sectioning, and subjected to
immunohistochemistry for Ki67 and BAX expression. Positively
stained vs. total number of cells per colony were counted (N= 30,
mean ± SD, **P < 0.01). Scale bar 50 µm in b and e. b For compre-
hensive drug sensitivity testing (N= 1), MDA-MB-453 cells were
treated with 527 compounds in ﬁve-point dose either alone or in
combination with speciﬁc FGFR4 inhibitor BLU9931. Dotplot
showing the difference in DSS (drug sensitivity score) for cells in
treatment combination with BLU9931 (100 nM) versus single agent
treatments. Negative values are compounds inducing larger decreases
in viability as single agents; positive scores indicate compounds
yielding larger decreases in viability in the presence of BLU9931.
Colors demarcate compounds with similar class
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in vitro screen. We provide evidence suggesting that by
Y433-MST1 phosphorylation, FGFR4 inhibits MST1/2
activation. In endogenous FGFR4+/HER2+ breast cancer
cell model, this inhibition was essential to counteract
apoptosis induction. By this mechanism, FGFR4 can
increase cell survival in breast cancers, where fast pro-
liferation is driven by HER/ERBB and FGFR4 signaling [4,
5]. In addition, supporting this conclusion, FGFR4 over-
expression was associated with poor HER2+ breast cancer
patient survival.
MST1 and MST2 are the core kinases of mammalian
Hippo tumor suppressor pathway, which complex and
context-dependent regulatory mechanisms in health and
disease still remain unclear. What is known is that MST1/2
are activated via homo- or heterodimerization followed by
trans-phosphorylation at T183/180 [19, 60]. Upon apopto-
sis, caspase-3-mediated cleavage removes the C-terminal
MST1/2 regulatory and nuclear export signals, triggering
nuclear translocation of the active N-terminal kinase [20,
21]. Although MST1/2 activity has been implicated in
histone phosphorylation and chromatin condensation,
functional contribution of endogenous MST1/2 to apopto-
sis, downstream of caspase-3, remains unclear [19, 21, 61,
62]. Here, we show that in FGFR4+/HER2+ breast cancer
cells, particularly under tumor-mimicking 3D conditions,
FGFR4 depletion-induced MST1/2 autophosphorylation
coupled with MST1 cleavage and nuclear localization
without additional stimuli. This resulted in signiﬁcant
apoptosis induction, which was rescued back to low levels
by double knockdown of FGFR4 with MST1 or MST2. In
cells with endogenous FGFR4, however, MST1 or
MST2 silencing did not reduce apoptosis, suggesting that
the cells have developed dependency of the herein identiﬁed
FGFR4-mediated suppression of apoptosis. Moreover,
pharmacological FGFR4 targeting speciﬁcally sensitized
the cells, in addition to HER2/EGFR and PI3K/AKT/
mTOR inhibitors, to the modulators of mitochondrial
apoptosis pathway, suggesting interesting possibilities also
for combinatorial treatments to effectively halt the FGFR4
+/HER2+ cancers [63].
Previously, other kinases have been indicated in positive
and negative MST1/2 regulation [31, 64–67]. In neuronal
cells, MST1 phosphorylation by non-receptor tyrosine
kinase c-Abl at Y433 (conserved site in mammals, absent in
MST2) leads to MST1 stabilization and activation thus
increasing cell death [68], an opposite outcome from the
herein identiﬁed FGFR4-mediated inhibition of MST1/2
and apoptosis. Moreover, c-Abl-mediated phosphorylation
of Y81 on MST2 (species-conserved site, absent in MST1)
enhances MST2 activation [69]. Our current results indicate
that, although involving speciﬁc MST1/N cleavage and
suppression upon MST1 phosphorylation (pY433), the
apoptosis induction by FGFR4 depletion required combined
activity of MST1 and MST2, whereas these individual
kinases were regulated even in an opposite manner. This
can be related to the mechanisms whereby AKT signaling
differentially regulates MST1 and MST2 [54, 70], and
MST1/2 integrate signals from Ras signaling (Raf-1,
RASSF1A) [54, 60, 71, 72]. As recombinant MST1 activity
was not inhibited by FGFR4 in vitro, we suggest that
FGFR4 likely alters MST1/2 activities via MST1-pY433-
regulated interactions. Further context-dependent aspects of
MST2 phosphorylation, (hetero)dimerization, signaling
scaffolds, and activity or cleavage regulation will remain
interesting future study subjects. Moreover, the other herein
identiﬁed unique MST1-pS410 phosphosite detected only in
the absence of FGFR4 activity and pY433, raises the pos-
sibility of mutually regulated phosphorylation of these
residues. The two MST1 phosphosites detected indepen-
dently of pY433 have been characterized; S320 as a phos-
phorylation site for anti-apoptotic CK2 [73], and T177 as a
MST1 activity-dependent site [74]. Therefore, the context-
dependent net effects of all MST1 phosphosites on its
activity regulation, including contributions by kinases other
than FGFR4, will be of interest. Nevertheless, current
results show that active FGFR4 tyrosine phosphorylates and
inactivates the pro-apoptotic MST1/2 serine/threonine
kinase in breast cancer cells, thus revealing a novel
mechanism of RTK-mediated apoptosis evasion and onco-
genic FGFR4 function.
Apart from pro-apoptotic nuclear functions, cytoplasmic
MST1/2 act on canonical Hippo signaling, which negatively
regulates YAP by serine phosphorylation and cytoplasmic
retention [19, 75]. In cancer, however, non-canonical reg-
ulation of YAP expression, localization and activity fre-
quently prevails along with the loss of balancing feed-back
mechanisms of normal cellular homeostasis [18, 75, 76].
We tested if FGFR4-mediated pro-apoptotic MST1/2 inhi-
bition also regulated YAP. Although YAP (pS127 and total)
was decreased in FGFR4-overexpressing breast cancers
(TCGA RPPA), the FGFR4-dependent and -independent
modulation of MST1/2 had variable effects on YAP S127
phosphorylation or localization. This is consistent with
accumulating evidence acknowledging cell polarity, junc-
tional complexes, and cytoskeletal signals as important
YAP regulators even independent of MST1/2 [17, 66]. A
further interesting aspect is that FGFR1, -2, and -4 are
transcriptional targets of YAP, and a feed-forward loop has
been described between YAP and FGFR signaling in cho-
langiocarcinoma and ovarian cancer [77, 78].
In conclusion, the identiﬁed oncogenic FGFR4 activity
explains mechanistically how RTKs such as FGFR4 can
confer aggressiveness to certain cancer cells via apoptosis
resistance. As FGFR4 is suitable for targeting, these results
raise tempting questions, whether FGFR4 inhibition in
HER2+ breast cancer would release the intrinsic MST1/2-
2590 S. P. Turunen et al.
mediated apoptotic machinery. And if so, would it offer
increased efﬁcacy in combination with targeting HER2,
AKT/mTOR, and/or mitochondrial apoptosis pathways in
this cancer subset, or in other FGFR4-overexpressing can-
cers? Nonetheless, the identiﬁcation of MST1/2 as direct
substrates for FGFR4, and FGFR4-dependent inhibition of
MST1/2-dependent apoptosis, highlights interesting ave-
nues for FGFR4 targeting in anticancer treatments.
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